Today marks World Cancer Day, a significant date in the global health calendar that compels us to reflect on our collective journey in the battle against cancer. It is celebrated on February 4 every year. This day is not just about raising awareness, it’s a rallying cry for organizations, communities, and individuals worldwide to close the care gap and ensure equitable access to cancer care for all.
The March Forward: Celebrating Advances in Cancer Research
The past year has been a testament to human resilience and scientific ingenuity, showcasing significant breakthroughs in cancer research. Innovations in targeted therapies, immunotherapy, and early detection technologies are paving the way for more personalized and effective treatment options.
Let’s check several articles published since WCD 2023 that highlight the diverse and ongoing progress in the fight against cancer:
- Introduction: The history of cancer survivorship programs in the USA: progress, challenges, and opportunities, by Larissa Nekhlyudov – Discusses the evolution of cancer survivorship programs in the USA, highlights the history of survivorship programs at eight US cancer centers, focusing on the progress and challenges faced. Despite the notable challenges, each center achieved major accomplishments in care delivery for a large number of survivors. This progress highlights the success and continuing evolution of survivorship care delivery to accommodate the unique needs of survivors and the systems in which they are treated. Published in the Journal of Cancer Survivorship, 2023.
- Advanced technologies towards improved HPV diagnostics, by Martin Bartosik, Ludmila Moráňová, Nasim Izadi. PhD, Johana Strmiskova, RAVERY SEBUYOYA, Jitka Holčáková, Roman Hrstka – Highlights advancements in diagnostics for HPV, aiming to reduce associated mortality and financial burden. Published in the Journal of Medical Virology, 2024.
- CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer, by Abudureyimu Tuerhong, Jin Xu, Wei Wang, Si Shi, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Xianjun Yu, Chen Liang – This study discusses the progress in pancreatic cancer treatment and explores the roles of CPT1B in enhancing the proliferative ability and metastasis of pancreatic cancer cells. Published in Surgery, 2024.
- Effect, main targets, and molecular mechanisms of glycyrrhiza-derived flavonoids on malignant tumor in comprehensive cancer treatment, by Wei Hu, Wenzhe Ma, Bo Li, Yu Hou , Rongyang Dai – Focuses on understanding the effects and research progress of glycyrrhiza-derived flavonoids in treating malignant tumors. Published in the Tropical Journal of Pharmaceutical Research, 2024.
- Social and Biological Determinants in Lung Cancer Disparity, by Briana A. Brock, Hina Mir, Flenaugh, Eric, Gabriela Oprea-Ilies, Rajesh Singh and Shailesh Singh – Addresses the challenges in improving the survival rates of lung cancer patients despite advancements in treatment. This review highlights the relationship between social factors and the biology of lung cancer contributing to disparities in incidence and outcome. Published in Cancers, 2024.
- MDMX in Cancer: A Partner of p53 and a p53-Independent Effector, by Wu Lin, Yuxiang Yan, Qingling Huang andDali Zheng – Reviews current research on MDMX’s role in cancer and its potential as a target for developing more specific and effective inhibitors for cancer treatment. Published in Biologics: Targets and Therapy, 2024.
- ADaM Design and Programming Standardization for Oncology Efficacy Endpoints Based on RECIST 1.1, by Zihui (Ellen) Lin, Matt Ness, and Yinghui Wang: PharmaSUG, 2023.
Cancer research continues to make remarkable strides, offering hope to millions affected by this disease. Scientists and healthcare professionals are dedicated to unraveling the complexities of cancer, leading to improved treatments, increased survival rates, and enhanced quality of life for patients.
FDA: Submitting Patient Reported Outcome Data in Cancer Clinical Trials
Last year, a significant update was made in the regulatory process – Submitting Patient-Reported Outcome Data in Cancer Clinical Trials was released; it highlights the importance of standardized methods for collecting, analyzing, and submitting PRO data to regulatory bodies like the FDA, where a PRO is a type of clinical outcome assessment (COA) used to collect patient experience data. By emphasizing the patient’s perspective in assessing treatment efficacy and quality of life, this update underlines the commitment to making cancer treatment more patient-centered. It explores how these standards facilitate a deeper understanding of the patient experience, potentially leading to more personalized and effective cancer care strategies.
Uplifting Those Affected by Cancer
and compassion to those touched by cancer. We encourage you to explore the post “Embrace Life and Well-being: “I CHOOSE LIFE” Documentary on World Cancer Day 2024” by Petra Thaller, OAC Outdoor Against Cancer with impactful and inspiring documentary!
We honor both those undergoing treatment and survivors who are forging new paths post-cancer. Their fierce spirit is nothing short of inspiring. Sharing these stories of perseverance and victory brings light even on the most challenging of days, reminding us of the indomitable human spirit that thrives in communal support and shared resilience.
Committing to Continued Cancer Research
Our resolve in pursuing cancer research stands firm. TUNECT CRO is unyielding in its search for innovative pathways that will eventually demote cancer from a dreaded ailment to a manageable condition. Our international collaborations reflect our commitment to this cause, motivated by the united efforts of the wider research community.
Joining Forces on World Cancer Day 2024
As we commemorate World Cancer Day 2024, let us renew our dedication to advancing cancer research, supporting patients, and striving for a future where cancer is no longer a threat. Together, we can continue to make strides towards more personalized, effective cancer care, honoring the resilience and courage of every individual affected by this disease.